Improved in vitro toxicity tests are currently required, mainly due to the new European Chemicals Legislation (REACH). As a result, hepatocytes as test models are highly relevant because most xenobiotics are either metabolically activated or detoxified in the liver. However, the cultivation of isolated hepatocytes in vitro is difficult. Depending on culture conditions they may dedifferentiate and massively alter their functions compared to the in vivo situation. Recently, we have identified several factors involved in early signalling which are responsible for the observed in vivo/in vitro discrepancies (Godoy et al., 2009). We have also established techniques to manipulate signalling network constellations in order to guarantee in vivo like functions of cultivated hepatocytes. After introducing these improvements, hepatocyte in vitro systems can also be applied to -omics studies in which toxic substances are classified by gene or protein expression patterns with respect to their molecular mechanisms of action.


Further videos with hepatocytes, including interactions with endothelial cells and tumour cells, can be seen here.
Together with the research groups of Christoph van Thriel (IfADo) and Jonathan West (ISAS), we have established screening techniques for neurotoxic compounds inhibiting the formation of neurite connections (funded by the EC project ESNATS). A long term goal of this project is to integrate the above described in vitro systems with hepatocytes into the neurite connection assay in order to achieve neurotoxicity testing with and without hepatic metabolism.

Godoy P, Hengstler JG, Ilkavets I, Meyer C, Bachmann A, Müller A, Tuschl G, Mueller SO, Dooley S. Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. Hepatology. 2009 Jun;49(6):2031-43.
Brulport M, Schormann W, Bauer A, Hermes M, Elsner C, Hammersen FJ, Beerheide W, Spitkovsky D, Härtig W, Nussler A, Horn LC, Edelmann J, Pelz-Ackermann O, Petersen J, Kamprad M, von Mach M, Lupp A, Zulewski H, Hengstler JG: Fate of extrahepatic human stem and precursor cells after transplantation into mouse livers. Hepatology 2007;46:861-70.
Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007;39:159-234.
Hengstler JG, Utesch D, Steinberg P, Ringel M, Swales N, Biefang K, Platt KL, Diener B, Böttger T, Fischer T, Oesch F, Cryopreserved primary hepatocytes as an in vitro model for the evaluation of drug metabolism and enzyme induction. Drug Metab Rev 32, 81-118, 2000.
Aurich H, Sgodda M, Kaltwaßer P, Vetter M, Weise A, Liehr T, Brulport M, Hengstler JG, Dollinger MM, Fleig WE, Christ B. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. GUT 2009;58:570-81.
Aurich I, Mueller LP, Aurich H, Luetzkendorf J, Tisljar K, Dollinger M, Schormann W, Walldorf J, Hengstler J, Fleig WE, Christ B. Functional integration of human mesenchymal stem cell-derived hepatocytes into mouse livers. Gut. 2007;56(3):405-415.
Ruhnke M, Ungefroren H, Nussler A, Martin F, Brulport M, Schormann W, Hengstler JG, Klapper W, Ulrichs K, Hutchinson JA, Soria B, Parwaresch RM, Heeckt P, Kremer B, Fändrich F, Reprogramming of Human Peripheral Blood Monocytes into Functional Hepatocyte and Pancreatic Islet-like Cells. Gastroenterology, 128:1774-86, 2005.
Weng HL, Liu Y, Chen JL, Huang T, Xu LJ, Godoy P, Hu JH, Zhou C, Stickel F, Marx A, Bohle RM, Zimmer V, Lammert F, Mueller S, Gigou M, Samuel D, Mertens PR, Singer MV, Seitz HK, Dooley S. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology. 2009 Jul;50(1):230-43.
Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A, Breitkopf K, Weng H, Mertens PR. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology. 2008 Aug;135(2):642-59.